EC grants Orphan Drug Designation to proACTINA for tetrofosmin for diagnosis of Glioma

Athens, 26/10/2016

proACTINA SA, a research-driven and innovation-focused Small-Medium Enterprise in Athens-Greece, today announced that European Commission (EC) has granted Orphan Designation for tetrofosmin for the diagnosis of glioma, following a positive opinion by European Medicines Agency (EMA). The Decision was published in the Community Register of Orphan Medicinal Products and the product has received EU orphan designation number: EU/3/16/1764

For the full press release see: Orphan designation press release